ArticleInternational journal of molecular sciences2017
Imipramine Protects against Bone Loss by Inhibition of Osteoblast-Derived Microvesicles.
Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Sorafenib generates microvesicle particles in non-small cell lung cancer.Tumor discovery · 2025Article
- Microvesicle inhibition enhances the therapeutic effects of ATRA in acute promyelocytic leukemia cells via changes in miRNAs: the promising antileukemic potential of imipramine.Clinical and experimental medicine · 2025Article
- Extracellular Vesicles in the Crosstalk of Autophagy and Apoptosis: A Role for Lipid Rafts.Cells · 2025Review
- Role of Extracellular Vesicles in the Pathogenesis of Brain Metastasis.Journal of extracellular biology · 2025Review
- Isolation of Extracellular Vesicle Subtypes from Primary Osteoblast Cultures.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Ceramide-mediated orchestration of oxidative stress response through filopodia-derived small extracellular vesicles.Journal of extracellular vesicles · 2024Article
- Extracellular vesicles in acute respiratory distress syndrome: Understanding protective and harmful signaling for the development of new therapeutics.Histology and histopathology · 2024Review
- Extracellular vesicles in the glioblastoma microenvironment: A diagnostic and therapeutic perspective.Molecular aspects of medicine · 2023Review
- Article
- Exosomes: A Tool for Bone Tissue Engineering.Tissue engineering. Part B, Reviews · 2022Review
- Exosome mediated biological functions within skeletal microenvironment.Frontiers in bioengineering and biotechnology · 2022Review
- Cellular Crosstalk in the Vascular Wall Microenvironment: The Role of Exosomes in Vascular Calcification.Frontiers in cardiovascular medicine · 2022Review
- Effects of Extracellular Osteoanabolic Agents on the Endogenous Response of Osteoblastic Cells.Cells · 2021Review
- Matrix Vesicles: Role in Bone Mineralization and Potential Use as Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Study on Transorgan Regulation of Intervertebral Disc and Extra-Skeletal Organs Through Exosomes Derived From Bone Marrow Mesenchymal Stem Cells.Frontiers in cell and developmental biology · 2021Review
- Review
- The Role and Impact of Extracellular Vesicles in the Modulation and Delivery of Cytokines during Autoimmunity.International journal of molecular sciences · 2020Review
- Review
- Extracellular Vesicles Mediate B Cell Immune Response and Are a Potential Target for Cancer Therapy.Cells · 2020Review
- The Potential Roles of Exosomal miR-214 in Bone Metastasis of Lung Adenocarcinoma.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The maintenance of bone homeostasis is largely dependent upon cellular communication between osteoclasts and osteoblasts. Microvesicles (MVs) represent a novel mechanism for osteoblasts and osteoclasts communication, as has been demonstrated in our previous study. Sphingomyelinases catalyze the hydrolysis of sphingomyelin, which leads to increased membrane fluidity and facilitates MV generation. This effect can be inhibited by imipramine, an inhibitor of acid sphingomyelinase (ASM), which is also known as a member of tricyclic antidepressants (TCAs). A recent study has reported that in vitro treatment of imipramine blocked MVs release from glial cells. However, whether imipramine has this effect on osteoblast-derived MVs and whether it is involved in MV generation in vivo is unclear. Here, our investigations found that imipramine slightly reduced the expression of osteoblast differentiation of related genes, but did not impact parathyroid hormone (PTH) regulation for these genes and also did not affect receptor activator of nuclear factor-κB ligand (RANKL)-mediated osteoclast formation; however, imipramine treatment blocked MVs released from osteoblasts and inhibited MV-induced osteoclast formation. In vivo, mice administrated with imipramine were protected from ovariectomy-induced bone loss as evaluated by various bone structural parameters and serum levels of biochemical markers. Our results suggest that inhibiting the production of MVs containing RANKL in vivo is very important for preventing bone loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.